The DUA legally binds the user to the Agreement’s terms. The user must agree to all the terms and sign off on them prior to the release or access to data files containing protected health information, and individual identifiers. The DMP SAQ is a technical, evidence-based questionnaire that DUA users must complete as part of the data request packet. The DMP SAQ will enable CMS to evaluate researcher data systems to ensure that CMS data are adequately secured and appropriately protected, as per the Privacy Act and the HIPAA Privacy Rule. The DMP SAQ also allows CMS to measure compliance through the implementation of security and privacy controls as outlined in the National Institute of Standards and Technology (NIST) Special Publication 800-53 and the Centers for Medicare & Medicaid Services (CMS) Information Security and Acceptable Risk Safeguards (ARS). The second component of the DMP SAQ is to provide ongoing oversight. All organizations will be subject to routine audits of the environments used to store and process CMS data, as described in their organizational-level DMP SAQ. Form Number: CMS–10733 (OMB control number: 0938-New); Frequency: Annually; Affected Public: Private Sector, State, Local, or Tribal Governments, Federal Government, Business or other for-profits, Not-for-profits institutions; Number of Respondents: 1,000; Total Annual Responses: 1,000; Total Annual Hours: 1,500. (For policy questions regarding this collection contact James Krometis at 410–786–0340.)


William N. Parham, III, Director, Paperwork Reduction Staff, Office of Strategic Operations and Regulatory Affairs.


Agency Information Collection Activities; Announcement of Office of Management and Budget Approvals

AGENCY: Food and Drug Administration, HHS.

SUMMARY: The Food and Drug Administration (FDA) is publishing a list of information collections that have been approved by the Office of Management and Budget (OMB) under the Paperwork Reduction Act of 1995.

FOR FURTHER INFORMATION CONTACT: Ila S. Mizrahi, Office of Operations, Food and Drug Administration, Three White Flint North, 10A–12M, 11601 Landsdown St., North Bethesda, MD 20852, 301–796–7726, PRAMain@fda.hhs.gov.

SUPPLEMENTARY INFORMATION: The following is a list of FDA information collections recently approved by OMB under section 3507 of the Paperwork Reduction Act of 1995 (44 U.S.C. 3507). The OMB control number and expiration date of OMB approval for each information collection are shown in table 1. Copies of the supporting statements for the information collections are available on the internet at https://www.reginfo.gov/public/do/PRAMain. An Agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number.

<table>
<thead>
<tr>
<th>Title of collection</th>
<th>OMB control No.</th>
<th>Date approval expires</th>
</tr>
</thead>
<tbody>
<tr>
<td>Infant Formula Recall Regulations</td>
<td>0910–0188</td>
<td>12/31/2023</td>
</tr>
<tr>
<td>State Petitions for Exemption from Preemption</td>
<td>0910–0277</td>
<td>12/31/2023</td>
</tr>
<tr>
<td>Product Jurisdiction and Combination Products</td>
<td>0910–0523</td>
<td>12/31/2023</td>
</tr>
<tr>
<td>Exceptions or Alternatives to Labeling Requirements for Products Held by the Strategic National Stockpile</td>
<td>0910–0614</td>
<td>12/31/2023</td>
</tr>
<tr>
<td>Generic Clearance for the Collection of Qualitative Feedback on Food and Drug Administration Service Delivery</td>
<td>0910–0697</td>
<td>12/31/2023</td>
</tr>
<tr>
<td>Registration of Human Drug Compounding Outsourcing Facilities Under Section 503B of the FFDCA and Associated Fees Under Section 744K</td>
<td>0910–0776</td>
<td>12/31/2023</td>
</tr>
</tbody>
</table>


Lauren K. Roth,
Acting Principal Associate Commissioner for Policy.

[FR Doc. 2021–03254 Filed 2–17–21; 8:45 am]

BILLING CODE 4120–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Substance Abuse and Mental Health Services Administration

Center for Substance Abuse Treatment; Notice of Meeting

Pursuant to Public Law 92–463, notice is hereby given that the Substance Abuse and Mental Health Services Administration’s (SAMHSA) Center for Substance Abuse Treatment (CSAT) National Advisory Council (NAC) will meet on March 31, 2021, 1:00 p.m.–6:00 p.m. (EDT).

The meeting is open to the public and will include consideration of minutes from the SAMHSA CSAT NAC meeting of September 22, 2020; an update on CSAT activities; a discussion with SAMHSA leadership; a discussion about the use of technology in prevention and treatment of substance use disorders; and a discussion on rural and frontier communities.

The meeting will be held via WebEx and telephone only. Interested persons may present data, information, or views, orally or in writing, on issues pending before the Council. Oral presentations from the public will be scheduled at the conclusion of the meeting. Individuals interested in making oral presentations or written submissions must notify the contact person on or before March 19, 2021. Up to five minutes will be allotted for each presentation.

Registration is required to participate. To attend virtually, or to obtain the call-in number and access code, submit written or brief oral comments, or request special accommodations for persons with disabilities, please register on-line at http://snacregister.samhsa.gov/MeetingList.aspx, or communicate with the CSAT National Advisory Council Designated Federal Officer (see contact information below).

Meeting information and a roster of Council members may be obtained by accessing the SAMHSA Committee

ACTION: Notice.